Pfizer Inc. (NYSE:PFE) Shares Acquired by Edgestream Partners L.P.

Edgestream Partners L.P. increased its position in shares of Pfizer Inc. (NYSE:PFE) by 1,704.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,967 shares of the biopharmaceutical company’s stock after acquiring an additional 149,212 shares during the period. Edgestream Partners L.P.’s holdings in Pfizer were worth $4,420,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PFE. Olistico Wealth LLC acquired a new stake in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the second quarter worth $34,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE PFE opened at $29.83 on Wednesday. The company has a fifty day moving average of $29.30 and a two-hundred day moving average of $28.18. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.12. The company has a market capitalization of $169.04 billion, a PE ratio of -497.08, a P/E/G ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter last year, the business posted $0.67 EPS. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were given a $0.42 dividend. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.63%. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Wall Street Analyst Weigh In

Several research firms recently commented on PFE. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Barclays boosted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday. Finally, Wells Fargo & Company lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.